A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
Extensive-Stage Small Cell Lung Cancer
DRUG: Adebrelimab +Etoposide+Platinum-based drugs|DRUG: Maintenance treatment period:
Progression-free survival（PFS）, First-line treatment with adebelimab plus chemotherapy for sequential adebelimab plus apatinib maintenance therapy for progression-free survival (PFS) in patients with extensive-stage small cell lung cancer, 12 months
Objective response rate（ORR）, Objective response rate (ORR) of adebelimab plus chemotherapy in first-line treatment of sequential adebelimab plus apatinib maintenance therapy in patients with extensive-stage small cell lung cancer, 12 months|Disease control rate（DCR）, Disease control rate (DCR) of adebelimab plus chemotherapy in first-line treatment of sequential adebelimab plus apatinib maintenance therapy in patients with extensive-stage small cell lung cancer, 12 months
This study aims to evaluate the efficacy (PFS, ORR, DCR, OS) and safety of adebelimab in combination with chemotherapy as a first-line treatment for the maintenance treatment of adebelimab plus Apatinib Mesylate Tablets with extensive-stage small cell lung cancer